Kornimate/medical-research-clean huggingface dataset:
simultaneous assessment of ffr and spect

Conditions: Coronary Artery Disease

Summary: the overall purpose of this research study is to identify the disparity in ischemia measurement between fractional flow reserve (ffr) used in the cardiac catheterization laboratory and myocardial perfusion stress- single-photon emission computed tomography (spect). this study aims to determine the correlation between simultaneous ffr and spect obtained using regadenoson in the catheterization laboratory.

patients who are previously scheduled for diagnostic coronary angiography will be approached for consent to be part of the study. if the patient is found to have one or two vessel disease and it is planned by the interventional cardiologist that ffr will be used, then the previously consented patient will be deemed appropriate for the study. the standard procedure will be followed for ffr testing using regadenoson. the patient will then receive the standard dose of tc-99m sestamibi. the interventional cardiologist will proceed with percutaneous coronary intervention (pci) if appropriate. patients will proceed to the cardiac catheterization laboratory holding area post procedure. patients will then be scheduled to be taken to the nuclear cardiology laboratory one to three hours following the coronary angiogram for standard spect acquisition. patients will be monitored for 2-6 hours or overnight as clinically indicated following diagnostic coronary angiography and pci. low dose resting myocardial perfusion scanning may be performed the next day if stress myocardial perfusion study was abnormal.

Eligibility criteria:
inclusion criteria: patients undergoing clinically-indicated ffr measurement (to determine the hemodynamic significance of intermediate degrees of stenosis) for single or two -vessel epicardial coronary disease during diagnostic coronary angiography for suspected coronary artery disease. exclusion criteria: 1. patients with 3-vessel disease 2. prior coronary artery bypass grafting 3. patients with second or third- degree atrioventricular block, without a functioning pacemaker 4. patients who have ingested caffeine-containing products within the past 12 hours.
study of inhaled nitric oxide (ino) and respiratory outcomes in late preterm infants

Conditions: Bronchopulmonary Dysplasia

Summary: the aim of this study is to determine if inhaled nitric oxide will improve short and long term respiratory outcomes in preterm infants. infants born at a gestational age of 30-36 weeks and who require breathing support with high flow nasal cannula, nasal continuous positive airway pressure, or nasal intermittent positive pressure will be randomized to receive either inhaled nitric oxide or placebo. the dose will then be decreased per protocol until all respiratory support has been discontinued. infants will be followed to evaluate safety and efficacy of non-invasive ino delivery, up to 12 months corrected gestational age.


Eligibility criteria:
inclusion criteria: * \<48 hours of age, * 30 - 36 weeks gestational age at birth based on best estimate using obstetrical sonography (first or second trimester), solid dating criteria, or ballard examination, * birth weight of ≥ 1,000 g, * 5 minute apgar score ≥5, * requiring nasal cannula o2 \> 1 liter per minute (lpm), continuous positive pressure (cpap), or non invasive positive pressure ventilation (nippv) for treatment of respiratory failure, * requiring a fraction of inspired oxygen (fio2) of at least 0.25 to maintain arterial oxygen saturation (sao2) 88-94%, * parent or guardian has signed informed consent and agrees to all study- related procedures, including those required after hospital discharge. exclusion criteria: * major congenital anomaly * intubation and surfactant in the delivery room or prior to enrollment in the neonatal intensive care unit (nicu). excludes intubation for suctioning. * known congenital infection (bacterial, viral), * perinatal asphyxia (5 minute apgar \<5, umbilical artery ph \< 7.0 or evidence of neonatal encephalopathy), * mother and/or infant is enrolled in another clinical trial (excluding observational) or has received an investigational drug, * has undergone or is anticipated to require a major surgical procedure within the first 48 h of life, * any condition which could preclude receiving study drug or performing any study-related procedures, * use of postnatal corticosteroids, * parent or guardian is unable or unwilling to complete study procedures after hospital discharge.

Keywords: inhaled nitric oxide bronchopulmonary dysplasia late prematurity chronic respiratory morbidity
association between cancer cells and normal versus (vs.) low levels of thyroid hormones in the serum

Conditions: Thyroid Cancer

Summary: much experimental data has suggested that thyroid hormones (t3 and t4) may modulate neoplastic cells and that t3/t4 deprivation may remove this stimulus. it is now well established that t3/t4 affects cell division/angiogenesis through binding to integrin avb3, commonly over-expressed on many cancer cells. in the experimental settings, mimicking hypothyroidism in the cells is a difficult task. currently, the use of charcoal stripped serum is used. using this method, the serum is stripped not only from t3 and t4, as intended, but also from central and important cytokines and growth factor. this leads to a reduced rate of cancer cell proliferation and thus, does not reflect the natural environment in which cancer cells residue under hypothyroid conditions. the investigators aim to characterize and establish the effects of serum from hypothyroid patients on the proliferation/viability of a variety of cancer cell models.


Eligibility criteria:
inclusion criteria: * hypothyroid state exclusion criteria: * non hypothyroid state

Keywords: hypothyroid and non hypothyroid
rate and predictors of relapse in the treatment of hepatitis c (study p05181)

Conditions: Hepatitis C, Chronic

Summary: this is an observational, multicenter, nationwide study where information will be collected on the follow-up of participants with chronic hepatitis c virus (hcv) who have a viral response at the end of treatment with pegylated interferon alfa-2b (peg ifn alfa-2b) plus ribavirin (rbv) administered according to the directions on the products' labeling. no administration of treatment is planned as a result of study enrollment.


Eligibility criteria:
inclusion criteria: * participants with chronic hepatitis c virus (hcv)\[any genotype\] who received pegylated interferon alfa-2b plus ribavirin as first treatment for hepatitis c. * negative hcv rna at the end of treatment (24 or 48 weeks according to the product labeling as appropriate), measured by the assay used at each institution. only institutions using an assay with a limit of detection of 50 iu/ml or less will be eligible. exclusion criteria: * women of childbearing potential (i.e., premenopausal women and women who are less than 6 months postmenopausal) who will not use an appropriate contraceptive method during the course of the clinical study. appropriate contraceptives include double barrier methods (eg, diaphragm or condom plus spermicide), intrauterine device, oral, injectable or subcutaneous hormonal contraceptive, or surgically sterilized partner. * completed treatment with pegylated interferon alfa-2b plus ribavirin more than 4 weeks before study entry. * positive hcv rna at the end of treatment (24 or 48 weeks according to the product labeling as appropriate). * participants treated for a period shorter than the enrollment period. * co-infection with human immumodeficiency virus (hiv). * co-infected with hepatitis b virus (hbv).
postural correctors & activity trackers in total knee replacement rehab

Conditions: Total Knee Replacement

Summary: * to assess the impact of postural corrector on post-operative knee function and activity * to evaluate the role of activity tracker in monitoring and enhancing post-operative rehabilitation * to assess the effects of postural corrector and activity tracker on pain management during rehabilitation

knee osteoarthritis is a major public health threat. chronic pain and incapacity related to knee degenerative arthritis (oa) is current among the older population in several developed countries and also the condition is marked by many pathological characteristics, like joint house narrowing and also the formation of osteophytes, despite the pressing want for effective hindrance and treatment methods, there's a scarcity of comprehensive demographic knowledge on the general prevalence of the un wellness and also the specific subgroups affected

Eligibility criteria:
inclusion criteria: * participants who fall in this category will be included in the study. * commercially available devices * post-operative total knee replacement * males and females * age 40 to 60 years exclusion criteria: * participants who fall in this category will be excluded from the study. * non wearable devices * patient had been through surgery more than 1 month * patients with any other disorder or disease

Keywords: pain knee function post-operative rehabilitation
sternal closure with sternumfix in patients with high risk

Conditions: Sternum Wound Infection; Nonunion of Fracture of Sternum

Summary: the primary objective is to establish if the sternumfix system improves sternal closure. the study should test the hypothesis that in a high risk patient population with increased risk for the development of sternal wound complications sternumfix will reduce the incidence of sternal healing complications. the control group will be treated with wire cerclage, the standard method of sternal closure.


Eligibility criteria:
inclusion: * patients undergoing elective cardiac surgery with a median sternotomy * age \>18 years * male and female sex * informed consent * patients with high risk for sternal wound complications patients are designated as high risk patients if they have either: * one or more major risk factors or * four or more minor risk factors. major risk factors are: * obesity: bmi \> 30. * diabetes: intake of oral anti-diabetic drugs and/or insulin at time of surgery. * copd: history of chronic coughing plus expectoration for at least 3 months by at least two consecutive years, plus evidence of restrictive pattern at spirometry. * planned bita: bilateral use of thoracic artery * age \> 75 years minor risk factors are: * history of smoking;(minimum of 1 year of history of smoking) * hyperlipoproteinaemia (as stated in the patient data) * planned surgery is a cabg * patient is on dialysis * repeat sternotomy * left ventricular ejection fraction \< 30% (as stated in the patient data) * male sex exclusion: * active infection * participation in a pharmaceutical clinical study or any trial with interfering endpoints within the last 30 days * pregnancy

Keywords: medical device sternal closure sternotomy dehiscence sternal wound healing randomized trial steel wire
efficacy and safety study of peginterferon alfa-2b in chinese chronic hepatitis c patients

Conditions: Chronic Hepatitis C

Summary: the purpose of this study is to evaluate the efficacy and safety of peginterferon alfa-2b (40kd, y shape, the followings will refer as ypeginterferon alfa-2b for short), at a dose of 180μg/week, in combination with ribavirin in chinese chronic hepatitis c patients. the study will first group patients into two sub-study, genotype 2/3 and non-genotype 2/3, depending on the hcv genotype that infected. in the genotype 2/3 sub-study about 219 patients will be enrolled, and eligible patients are randomized at 2:1 ratio into ypeginterferon alfa-2b group or active control group (pegasys), receiving 24 weeks of interferon therapy and oral daily ribavirin at a dose of 800mg/d. in the non-genotype 2/3 sub-study about 507 patients will be enrolled, and eligible patients are randomized at 2:1 ratio into ypeginterferon alfa-2b group or active control group (pegasys), receiving 48 weeks of interferon therapy and oral daily ribavirin 1000-1200mg/day , basing on body weight. all patients will be followed for 24 weeks after the end of therapy.


Eligibility criteria:
inclusion criteria: * 18\~65 years * hepatitis virus c chronic infection evidences: hcv rna or anti-hcv positive\>6 months,or other evidences supporting diagnosis of chronic hepatitis c infection * hcv rna≥2000iu/ml, anti-hcv positive at screening * pregnancy tests for female patients must be negative. all patients must take effective contraception measures during the study period * signed informed consent exclusion criteria: * pregnant or lactating women * mental or psychology disorder * anc\<1500/mm3, or plt\<90,000/mm3, or hb\<uln(upper limit of normal) * received interferon treatment within the previous 6 months or shown no-response to previous interferon treatment * co-infection with hiv, hav, hbv, hev * evidence of hepatic decompensation (e.g: child plug≥b, prothrombin time prolonged more than 3 seconds, tbil\>2uln, alb\<35g/l) * hepatocarcinoma or suffering from any other malignant tumor * not well controlled endocrine diseases(e.g:thyroid disfunction, mellitus mellitus) * significant function damage in any major organs (e.g: heart, lung, kidney) * involved in other investigation within the previous 3 months * other conditions which in the opinion of the investigator precluding enrollment into the study (e.g: poor compliance)

Keywords: peginterferon pegasys sustained virus response hcv
longitudinal study of the evoked compound action potential measured in children cochlear implant users

Conditions: Cochlear Nerve Disease

Summary: introduction: in cochlear implant (ci) users, the recording of the electrically evoked compound action potential (ecap) of the auditory nerve represents an option to assess changes in auditory nerve responses and the interaction between the electrode and the neural tissue over time. aim: to study ecap in children during the first year of ci use. material and methods: the ecap characteristics have been analyzed in 13 children implanted younger than three years old. series study. descriptors: cochlear implantation,cochlear nerve,child.


Eligibility criteria:
this study selected only children implanted younger than three years old and followed them during their first year of ci use.

Keywords: cochlear implantation. cochlear nerve. child. study ecap during first year
efficacy of plant-protein diets in patients with chronic kidney disease

Conditions: Chronic Kidney Disease Stage 5

Summary: the purpose of this study is to evaluate the efficacy of plant-protein diets for 12 weeks in patients with advanced chronic kidney disease.


Eligibility criteria:
inclusion criteria: 1. patients with chronic kidney disease who were referred to the outpatient department of nephrology at osaka university hospital 2. egfr \< 20 ml/min/1.73 m2 3. taking anigiotensin-converting enzyme inhibitors or angiotensin ⅱ receptor blockers or angiotensin receptor neprilysin inhibitor 4. k \< 5.5 meq/l exclusion criteria: 1. being planned to intitate renal replacement therapies within 3 months 2. having inflammatory bowel diseases 3. history of gastrointestinal tract surgery 4. taking antibiotics within 1 month before the entry 5. taking or being planned to start warfarin 6. having dietary allergies 7. having difficulty in oral intake 8. during pregnancy or breastfeeding 9. unsuitable for participant in the trial by an attending physician

Keywords: plant-protein diets chronic kidney disease uremic solutes metabolic acidosis chronic kidney disease-mineral and bone disorder gut microbiome
high flow oxygen and non invasive ventilation for hypercapnic respiratory failure

Conditions: Hypercapnic Respiratory Failure

Summary: this study evaluates high flow oxygen therapy in addition to non invasive ventilation (niv) to treat hypercapnic respiratory failure. between sessions of niv, half of participants will have high flow nasal cannula while the others will have standard low flow oxygen therapy.

high flow nasal cannula (hfnc) is a new way of oxygen therapy that has gained interest in the management of patients with acute respiratory failure. it allows reaching a high flow air up to 60 liters / min via a nasal cannula with a humidification and warming of the air administered. it has a number of physiological effects such as wash out of anatomical dead space, generation of a small peep and high inspired fraction of oxygen which enhances compliance and reduces inspiratory efforts. niv is the corner stone in the treatment of severe copd exacerbation. nevertheless, prolonged application of the facial mask expose to local complications and intolerance which can be a cause of failure, so reducing the duration of exposure to this procedure is important. the role of hfnc in supplementing niv effect during hypercapnic respiratory failure has not been assessed. much of the data available on hfnc are about hypoxemic respiratory failure. because of its physiological effects, it can be hypothesized that hfnc in addition to niv can shorten its duration by facilitating carbon dioxide clearance.

Eligibility criteria:
inclusion criteria: * patients aged more than 18 years with a diagnosis of acute-on-chronic respiratory failure and respiratory acidosis requiring niv. exclusion criteria: * patient included in another study * patients intubated at icu admission or within 12 hours * contraindication to niv including: pneumothorax, hemodynamic instability, gcs less than 12, facial malformation * asthma * a do not intubate order * neuromuscular disease

Keywords: high flow oxygen non invasive ventilation hypercapnic respiratory failure
effect of an low carbon high fat diet on pain- and quality of life in patients with lipedema

Conditions: Lipedema; Obesity, Morbid

Summary: lipedema is a chronic disease with unproportional, symmetrical fat accumulation in the lower extremities. patients experience pain in affected areas, and reduced quality of life. today's treatment is physiotherapy and surgery (liposuction). recent research shows that ketogenic-diet with low carbohydrate, high fat (lchf) conant can lead to reduced pain, increased quality of life and change in body composition. goals: investigate the effect of lchf diet on pain, quality of life and body composition.


Eligibility criteria:
inclusion criteria: * weight stable over the last three months (+ 2-3 kg) * not currently dieting to loose weight. * willing to meet for weekly follow-ups during the intervention and the reintroduction of a regular diet. * sign an informed consent before entering the study. exclusion criteria: * pregnant or breast feeding * history of infectious diseases * medication known to affect obesity * enrolment in any other obesity treatment * have had a bariatric surgery * history of psychological disorders * mentally disabled * not mastering a scandinavian language * having a malign disease or any disease that leads to dietary advice that is not consistent with intervention advices in the study

Keywords: diet, ketogenic pain quality of life body composition body fat distribution
vascular mechanisms for the effects of loss of ovarian hormone function on cognition in women

Conditions: Cognitive Impairment; Executive Dysfunction; Endothelial Dysfunction; Cardiovascular Disease

Summary: complaints about memory and thinking are common in women as they go through menopause and estrogen levels fall. the ovarian hormone estrogen is important for supporting normal cognitive function, and changes in brain activity and function occur when estrogen levels are decreased. estrogen is also important for maintaining healthy blood vessels which also support normal cognitive function. in alzheimer's disease and other types of dementia, there is significant damage to the blood vessels in the brain. this study will test whether changes in brain activity and function with the loss of estrogen are related to changes in vascular function. the investigators will measure vascular function using ultrasound, and brain activity using mri scans in women who are enrolled in the females, aging, metabolism and exercise (fame) study (nct01712230). in the fame study, healthy premenopausal women either take a medication to decrease their estrogen levels, or a placebo. this sub-study may provide new information about how estrogen affects vascular function and cognitive function, and lead to new ways to prevent or delay cognitive impairment or dementia.


Eligibility criteria:
inclusion criteria: 1. volunteers will be healthy women aged 40 to 60 years 2. are enrolled in the parent fame study (nct01712230). the investigators will consent up to 80 subjects with the aim of enrolling 17 in each of the 2 groups (placebo, gnrh agonist). exclusion criteria: 1. mini-mental state examination (mmse) score 27 or less 2. history of neurologic disease or major psychiatric illness 3. major depressive episode within the past 12 months 4. history of learning disability 5. less than high-school education 6. current smoking 7. use of psychoactive medications in the past 3 months (stable use of anti- depressant medication is allowed) 8. contraindications to mri scanning

Keywords: cognitive impairment executive function arterial stiffness endothelial function menopause women's health hormone therapy functional mri
oral topotecan versus intravenous docetaxel in pretreated, advanced non-small cell lung cancer

Conditions: Non-Small-Cell Lung Cancer

Summary: the purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * written informed consent * patients with advanced non-small cell lung cancer (nsclc). * patients who have received one previous chemotherapy for nsclc. * full recovery from previous chemotherapy. * presence of either measurable or non-measurable disease by radiologic study or physical examination. * at least 3 weeks since last major surgery (a lesser period is acceptable if deemed in the best interest of the patient). * at least 24 hours since prior radiotherapy providing that marked bone marrow suppression is not expected. patients who have received radiotherapy must have recovered from any reversible side effects (e.g. nausea and vomiting). * laboratory criteria: patients must have adequate bone marrow reserve and adequate kidney and liver function. exclusion criteria: * symptoms of brain metastasis (cancer spreading to the brain), requiring treatment with steroids. * active infection. * severe medical problems other than the diagnosis of nsclc, that would limit the ability of the patient to follow study guidelines or expose the patient to extreme risk. * ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of nsclc. * use of investigational drug within 30 days prior to the first dose of study medication. * women who are pregnant or lactating. * patients of child-bearing potential refusing to practice adequate birth control methods. * patients with conditions which might alter absorption of an oral drug.

Keywords: nonsmall cell lung cancer advanced second-line topotecan hycamtin oral docetaxel